Journal of Cancer Research and Therapeutics

Scope & Guideline

Pioneering research for better patient outcomes.

Introduction

Welcome to your portal for understanding Journal of Cancer Research and Therapeutics, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0973-1482
PublisherWOLTERS KLUWER MEDKNOW PUBLICATIONS
Support Open AccessNo
CountryIndia
TypeJournal
Convergefrom 2005 to 2024
AbbreviationJ CANCER RES THER / J. Canc. Res. Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressWOLTERS KLUWER INDIA PVT LTD, A-202, 2ND FLR, QUBE, C T S NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra 400059, INDIA

Aims and Scopes

The Journal of Cancer Research and Therapeutics focuses on the latest advancements in cancer research, therapeutic strategies, and clinical practices. It serves as a platform for disseminating innovative findings that enhance understanding and treatment of cancer, while also addressing the multifaceted challenges faced by oncology professionals.
  1. Clinical Trials and Therapeutics:
    The journal emphasizes the reporting of clinical trials and therapeutic interventions across various cancer types, providing insights into efficacy, safety, and patient outcomes.
  2. Molecular and Cellular Biology of Cancer:
    Research on the molecular mechanisms underlying cancer development and progression is a core focus, including studies on genetic mutations, signaling pathways, and tumor microenvironment interactions.
  3. Radiotherapy and Interventional Techniques:
    The journal includes research on advancements in radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT) and brachytherapy, as well as interventional approaches like ablation and chemoembolization.
  4. Cancer Epidemiology and Prevention:
    Epidemiological studies exploring risk factors, prevention strategies, and population-based cancer trends are highlighted to inform public health initiatives.
  5. Innovative Diagnostic Approaches:
    The journal covers novel diagnostic techniques, including imaging advancements and biomarker discovery, that aid in the early detection and accurate characterization of tumors.
  6. Patient Care and Quality of Life:
    Research addressing the psychosocial aspects of cancer care, including quality of life assessments and supportive care strategies, is integral to the journal's scope.
The Journal of Cancer Research and Therapeutics has witnessed emerging themes that reflect the dynamic nature of cancer research, driven by technological advances and changing patient needs. These trends highlight the journal's commitment to addressing contemporary challenges in oncology.
  1. Immunotherapy and Personalized Medicine:
    There is a growing emphasis on research related to immunotherapy approaches and personalized treatment plans tailored to individual genetic profiles, reflecting a paradigm shift in cancer treatment.
  2. Molecular Targeted Therapy:
    Studies focusing on targeted therapies that inhibit specific molecular pathways are increasingly prominent, showcasing advancements in drug development and efficacy.
  3. Artificial Intelligence and Machine Learning in Oncology:
    The integration of AI and machine learning techniques in cancer diagnosis, treatment planning, and outcome prediction is a rapidly emerging area, enhancing the precision of oncology practices.
  4. Cancer Genomics and Biomarkers:
    Research into cancer genomics, including the identification of biomarkers for early detection and therapeutic response, is on the rise, facilitating advancements in precision oncology.
  5. Quality of Life and Patient-Centered Care:
    There is an increasing focus on research that evaluates the quality of life for cancer patients, addressing the psychosocial aspects of treatment and survivorship.
  6. Novel Therapeutic Delivery Systems:
    Emerging studies on innovative drug delivery systems, such as nanoparticles and nanocarriers, are gaining traction as they promise to enhance the efficacy of cancer therapies.

Declining or Waning

While the Journal of Cancer Research and Therapeutics continues to evolve, certain research areas have experienced a decline in focus. This shift may reflect changes in scientific interest, advancements in technology, or the emergence of more pressing issues in cancer research.
  1. Traditional Chemotherapy Studies:
    Research specifically focused on traditional chemotherapy regimens has waned, possibly due to the increasing interest in targeted therapies and immunotherapies that offer improved outcomes.
  2. Single-Agent Studies:
    There has been a noticeable decrease in studies evaluating the efficacy of single-agent therapies, as the trend shifts towards combination therapies that leverage synergistic effects.
  3. Basic Science Research on Common Cancer Types:
    Basic research on well-characterized cancer types (e.g., breast, lung) has reduced, as researchers increasingly explore rarer malignancies or investigate complex interactions in tumor biology.
  4. Conventional Imaging Techniques:
    The reliance on conventional imaging modalities for cancer diagnosis is declining, as advanced techniques such as molecular imaging and radiomics gain prominence.
  5. Palliative Care Research:
    While still important, the volume of research specifically focused on palliative care strategies has decreased, possibly overshadowed by curative treatment advancements.

Similar Journals

Cancer Research Communications

Elevating cancer research to new heights.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

PROSTATE

Advancing knowledge in urology and oncology.
Publisher: WILEYISSN: 0270-4137Frequency: 16 issues/year

PROSTATE is a premier, peer-reviewed journal published by Wiley, focusing on the critical fields of urology and oncology. With an established history since 1980 and a projected convergence through 2024, this influential journal serves as a vital resource for researchers, clinicians, and students alike. It holds a prestigious position in the academic landscape, classified in the Q1 category for Urology and Q2 in Oncology as of 2023, demonstrating its significant contribution to these disciplines. With a Scopus rank of #23 in Urology and #169 in Oncology, PROSTATE is pivotal for advancing knowledge and fostering innovation in prostate research, treatment, and overall male health. The journal aims to publish high-quality original articles, reviews, and clinical studies that address the complexities of prostate-related conditions, ultimately seeking to improve patient outcomes and propagate best practices in the medical community.

CANCER GENE THERAPY

Advancing the Frontier of Cancer Treatment
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Cancer Medicine

Transforming cancer medicine with open access insights.
Publisher: WILEYISSN: 2045-7634Frequency: 12 issues/year

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.

CANCER LETTERS

Elevating the discourse in cancer science.
Publisher: ELSEVIER IRELAND LTDISSN: 0304-3835Frequency: 28 issues/year

Cancer Letters, a leading journal published by Elsevier Ireland Ltd, is dedicated to advancing the field of oncology and cancer research. With a rich history that spans from 1975 to 2024, this esteemed journal has established itself as a vital resource within the scientific community, holding a prestigious Q1 status in both Cancer Research and Oncology categories as of 2023. With an impressive ranking of #26/404 in Medicine _ Oncology and #19/230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, Cancer Letters sits in the top percentiles of its field, reflecting its high impact and relevance. Although it does not currently offer open access, the journal remains committed to disseminating paramount research findings, innovative methodologies, and critical reviews that inform and enhance ongoing studies in cancer therapeutics and patient care. Researchers, professionals, and students alike will find invaluable insights into the latest developments and discoveries in cancer research through the pages of Cancer Letters.

Wspolczesna Onkologia-Contemporary Oncology

Driving Clinical Applications with Groundbreaking Studies
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 1428-2526Frequency: 4 issues/year

Wspolczesna Onkologia - Contemporary Oncology is a leading open-access journal dedicated to the field of oncology and radiology, published by TERMEDIA PUBLISHING HOUSE LTD since 1999. With its ISSN 1428-2526 and E-ISSN 1897-4309, the journal has established a prominent place in scholarly publishing, contributing significantly to the advancement of cancer research and treatment modalities. Located in Poznań, Poland, it operates within a framework of high academic standards, currently holding a Q3 quartile ranking in Oncology and Q2 in Radiology, Nuclear Medicine, and Imaging for the year 2023. The journal serves as a valuable resource for researchers, medical professionals, and students alike, providing a platform for innovative studies and reviews that drive the clinical application of oncological practices. With its commitment to open access, Wspolczesna Onkologia allows for widespread dissemination of knowledge, ensuring that cutting-edge research is accessible to a global audience, thus bridging gaps in cancer care and fostering collaborative advancements in the field.

CANCER INVESTIGATION

Transforming knowledge into breakthroughs in cancer care.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

CANCER RESEARCH

Elevating the standards of cancer research and innovation.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 0008-5472Frequency: 24 issues/year

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

INTERNATIONAL JOURNAL OF CANCER

Catalyzing progress in the fight against cancer.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

American Journal of Cancer Research

Driving Collaboration in Cancer Science
Publisher: E-CENTURY PUBLISHING CORPISSN: 2156-6976Frequency: 12 issues/year

The American Journal of Cancer Research, with an ISSN of 2156-6976, is an esteemed publication in the field of oncology, dedicated to disseminating high-quality research in cancer biology, treatment advances, and molecular genetics. Published by E-CENTURY PUBLISHING CORP, this journal serves as a vital resource for oncologists, researchers, and students striving to advance their understanding of cancer mechanisms and therapeutic strategies. Though it has transitioned to a non-indexed status in Scopus since its coverage from 2012 to 2017, the journal continues to offer insightful contributions, situated within the 34th percentile in Medicine and Oncology and the 23rd percentile in Cancer Research. The open access availability empowers authors to share their knowledge widely, facilitating collaboration and progress in the battle against cancer. As the landscape of cancer research evolves, the American Journal of Cancer Research remains a significant platform for fostering dialogue and innovation in this critical area of healthcare.